

chain nodes :

11 12

ring nodes :

1 2 3 4 5 6 7 8

chain bonds :

5-12 8-11

ring bonds :

1-2 1-7 1-8 2-3 3-4 3-8 4-5 5-6 6-7

exact/norm bonds :

1-2 1-7 1-8 2-3 3-4 3-8 4-5 5-6 5-12 6-7 8-11

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 11:CLASS 12:CLASS

10/512,559

=> d his

(FILE 'HOME' ENTERED AT 20:38:05 ON 30 JAN 2007)

FILE 'REGISTRY' ENTERED AT 20:38:16 ON 30 JAN 2007

L1 STRUCTURE UPLOADED  
L2 QUE L1  
L3 4 S L2  
L4 STRUCTURE UPLOADED  
L5 QUE L4  
L6 4 S L5  
L7 640 S L2 SSS FUL  
L8 141 S L5 SUB=L7 FUL  
L9 114 S L8 AND CAPLUS/LC  
L10 27 S L8 NOT L9


FILE 'CAPLUS' ENTERED AT 20:41:32 ON 30 JAN 2007

L11 20 S L8

=> d 12

L2 HAS NO ANSWERS

L1 STR




Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

=> d 15

L5 HAS NO ANSWERS

L4 STR



10/512,559

Structure attributes must be viewed using STN Express query preparation.  
L5                    QUE   ABB=ON   PLU=ON   L4

=> d ibib abs hitstr total


~~LIT~~ ANSWER 1 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2006:1093757 CAPLUS  
 DOCUMENT NUMBER: 145:438634  
 TITLE: Preparation of acylaminopyrimidines as adenosine receptor antagonists  
 INVENTOR(S): Slee, Deborah; Lanier, Marion; Vong, Binh G.; Chen, Yongsheng; Zhang, Xiaohui; Lin, Emily; Moorjani, Manisha; Castro Palomino Laria, Julio Cesar  
 PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA; Almirall Prodesfarma, S.A.  
 SOURCE: PCT Int. Appl., 172pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006110884	A2	20061019	WO 2006-US13940	20060411
WO 2006110884	A3	20061123		
WO 2006110884	A8	20061214		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-670482P P 20050411  
 OTHER SOURCE(S): MARPAT 145:438634  
 GI



I

AB Title compds. [I; R1, R2 = (substituted) aryl, heteroaryl; R3 = (CR4R5)nR6, (CR4R5)nNR7R8, O(CR4R5)nR6, (CR4R5)nOR8; R4, R5 = H, OH, SH, NO2, cyano, amino, halo, (substituted) alkyl, alkoxy, alkylthio, cycloalkyl, alkylamino; R6 = (substituted) heterocyclyl; R7 = H, (substituted) alkyl; R8 = (CR4R5)nR6; NR7R8 = (substituted) heterocyclyl; n = 0-4], were prepared Thus, 1-tert-butoxycarbonylpiperidin-4-ylacetic acid was stirred 30 min. with (COCl)<sub>2</sub> and cat. DMF in THF to give a first

mixture; 2-(5-methyl-2-furyl)-6-(thiazol-2-yl)pyrimidin-4-amine (preparation given) in THF was treated with NaH and this second mixture was added dropwise to the first. mixture followed by stirring for 1 h to give coupling product, which was treated with CF<sub>3</sub>CO<sub>2</sub>H in CH<sub>2</sub>Cl<sub>2</sub> to give N-[2-(5-methylfuran-2-yl)-6-thiazol-2-ylpyrimidin-4-yl]-2-(1-methylpiperidin-4-yl)acetamide. In adenosine A<sub>2</sub>A receptor binding assays, I may have IC<sub>50</sub>'s of <10 μM.


IT 912939-22-1P 912939-23-2P 912939-25-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of acylaminopyrimidines as adenosine receptor antagonists)


RN 912939-22-1 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane-9-carboxylic acid, 3-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 912939-23-2 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane-3-acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-9-methyl- (9CI) (CA INDEX NAME)



RN 912939-25-4 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane-3-acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-9-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



10/512,559

11/ ANSWER 2 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:427357 CAPLUS

DOCUMENT NUMBER: 145:124531

TITLE: New Ligands with Affinity for the  $\alpha 4\beta 2$   
Subtype of Nicotinic Acetylcholine Receptors.

AUTHOR(S): Synthesis, Receptor Binding, and 3D-QSAR Modeling  
Audouze, Karine; Oestergaard Nielsen, Elsebet; Olsen,  
Gunnar M.; Ahring, Philip; Jorgensen, Tino Dyhring;  
Peters, Dan; Liljefors, Tommy; Balle, Thomas

CORPORATE SOURCE: NeuroSearch A/S, Ballerup, DK-2750, Den.  
SOURCE: Journal of Medicinal Chemistry (2006), 49(11),  
3159-3171

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:124531

AB A new series of piperazines, diazepanes, diazocanes, diazabicyclononanes, and diazabicyclodecanes with affinity for the  $\alpha 4\beta 2$  subtype of nicotinic acetylcholine receptors were synthesized on the basis of results from a previous computational study. A predictive 3D-QSAR model was developed using the GRID/GOLPE approach ( $R^2 = 0.94$ ,  $Q^2 = 0.83$ ,  $SDEP = 0.34$ ). The SAR was interpreted in terms of contour maps of the PLS coeffs. and in terms of a homol. model of the  $\alpha 4\beta 2$  subtype of the nicotinic acetylcholine receptors. The results reveal that hydrogen bonding from both hydrogens on the protonated amine and from the pyridine nitrogen to a water mol. as well as van der Waals interactions between the substituent bearing the protonated amine and the receptor is of importance for ligand affinity. The combination of 3D-QSAR and homol. modeling proved successful for the interpretation of structure-affinity relationships as well as the validation of the individual modeling approaches.


IT 387870-06-6P 653600-90-9P 897396-22-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, receptor binding, and 3D-QSAR modeling of new ligands with affinity for the  $\alpha 4\beta 2$  subtype of nicotinic acetylcholine receptors)

RN 387870-06-6 CAPLUS


CN 3,9-Diazabicyclo[4.2.1]nonane, 3-acetyl-9-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 653600-90-9 CAPLUS


CN 3,9-Diazabicyclo[4.2.1]nonane-3-carboxylic acid, 9-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/512,559



RN 897396-22-4 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decane-3-carboxylic acid, 10-(phenylmethyl)-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

30

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓  
 LIA ANSWER 3 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1082696 CAPLUS

DOCUMENT NUMBER: 144:6754

TITLE: Iodine-mediated cyclization of (4R,5R)-4,5-diamino-N,N'-bis[(1S)-1-phenylethyl]-1,7-octadiene - a stereoselective route to 2,5-diazabicyclo[2.2.1]heptanes

AUTHOR(S): Fiorelli, Claudio; Marchioro, Carla; Martelli, Gianluca; Monari, Magda; Savoia, Diego

CORPORATE SOURCE: Dipartimento di Chimica "G. Ciamician", Universita di Bologna, Bologna, 40126, Italy

SOURCE: European Journal of Organic Chemistry (2005), (18), 3987-3993

CODEN: EJOCFK; ISSN: 1434-193X

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:6754

AB Treatment of (4R,5R)-4,5-diamino-N,N'-bis[(1S)-1-phenylethyl]-1,7-octadiene with 2 equivalent of iodine in CH<sub>2</sub>Cl<sub>2</sub>/aqueous NaHCO<sub>3</sub> gave a mixture of two

quaternary ammonium salts in 70:30 ratio and almost quant. yield. The structure of the prevalent salt was determined by X-ray anal., which showed a bridged diazatricyclic skeleton, derived from two iodoamination steps, both involving the 5-exo cyclization of two 5-aminoalkene moieties, and an intramol. substitution involving the amine and iodide functions. The minor salt is an isomer of the prevalent one, formed by a pathway involving the stereospecific isomerization of the diastereomeric (iodomethyl)pyrrolidine produced in the first step to an (iodo)piperidine derivative via an aziridinium intermediate. Treatment of both products with different reagents, including (isopropyl)magnesium chloride, BuLi, Bu<sub>3</sub>SnH·Et<sub>3</sub>B, Cr(OAc)<sub>2</sub> and Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>, invariably gave the bridged piperazine (1S,3R,4S)-3-allyl-2,5-bis[(1S)-1-phenylethyl]-2,5-diazabicyclo[2.2.1]heptane by a retro reaction, and hydrogenolysis of the N-substituents and concomitant hydrogenation of the C=C bond were then achieved in the presence of Pd/C.

IT 869895-79-4P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of (iodomethyl)(aza)(azonia)tricyclononane derivative and study of

its conversion to 2,5-diazabicyclo[2.2.1]heptane and study of its crystal and mol. structures)

RN 869895-79-4 CAPLUS

CN 2H-1,5-Methanopyrrolo[3,2-b]pyrrolium, hexahydro-2-(iodomethyl)-1,4-bis[(1S)-1-phenylethyl]-, iodide, (1S,2R,3aR,5R,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT:


58

THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

applicant  
 ACCESSION NUMBER: 2004:101167 CAPLUS  
 DOCUMENT NUMBER: 140:146174  
 TITLE: Preparation of diazabicyclononanes and -decenes as opioid receptor ligands.  
 INVENTOR(S): Peters, Dan; Olsen, Gunnar M.; Nielsen, Elseber Ostegaard  
 PATENT ASSIGNEE(S): Neurosearch A/S, Den.  
 SOURCE: PCT Int. Appl., 22 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011468	A1	20040205	WO 2003-DK510	20030724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489165	A1	20040205	CA 2003-2489165	20030724
AU 2003280306	A1	20040216	AU 2003-280306	20030724
EP 1527075	A1	20050504	EP 2003-771053	20030724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1668621	A	20050914	CN 2003-817282	20030724
JP 2005536522	T	20051202	JP 2004-523742	20030724
NZ 537182	A	20060728	NZ 2003-537182	20030724
US 2005239773	A1	20051027	US 2005-521559	20050119
PRIORITY APPLN. INFO.:			DK 2002-1143	A 20020726
			WO 2003-DK510	W 20030724
OTHER SOURCE(S):		MARPAT 140:146174		
GI				



AB Title compds. [I; Q = CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>; 1 of R<sub>1</sub>, R<sub>2</sub> = (CH<sub>2</sub>)<sub>3</sub>R<sub>3</sub>, CH<sub>2</sub>CH:CHR<sub>3</sub>, CH<sub>2</sub>C.tplbond.CR<sub>3</sub>, the other = COR<sub>4</sub>; R<sub>3</sub> = (substituted) aryl, heteroaryl; R<sub>4</sub> = alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl], were prepared Thus, 1-[9H-3,9-diazabicyclo[4.2.1]non-3-yl]propan-1-one (preparation

given), K<sub>2</sub>CO<sub>3</sub>, and cinnamyl bromide were stirred 15 h in acetone to give 49% 1-[9-(3-phenylallyl)-3,9-diazabicyclo[4.2.1]non-3-yl]propan-1-one hydrochloride. The latter at 10  $\mu$ M showed 51% and 78% inhibition of  $\delta$ - and  $\kappa$ -receptors, resp.

IT 653600-80-7P 653600-81-8P 653600-82-9P


653600-83-0P 653600-84-1P 653600-85-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diazabicyclononanes and -decanes as opioid receptor ligands)


RN 653600-80-7 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(1-oxopropyl)-9-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 653600-81-8 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decane, 3-(1-oxopropyl)-10-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 653600-82-9 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-(1-oxopropyl)-3-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 653600-83-0 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(1-oxopropyl)-9-(3-phenyl-2-propenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 653600-84-1 CAPLUS  
 CN 3,10-Diazabicyclo[4.3.1]decane, 3-(1-oxopropyl)-10-(3-phenyl-2-propenyl)-,  
 (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 653600-81-8  
 CMF C20 H28 N2 O




CM 2

CRN 110-17-8  
 CMF C4 H4 O4

Double bond geometry as shown.



RN 653600-85-2 CAPLUS  
 CN 3,9-Diazabicyclo[4.2.1]nonane, 9-(1-oxopropyl)-3-(3-phenyl-2-propenyl)-,  
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 653600-87-4P 653600-89-6P 653600-90-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of diazabicyclononanes and -decans as opioid receptor ligands)

RN 653600-87-4 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(1-oxopropyl)-9-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


RN 653600-89-6 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane-3-carboxylic acid, 9-(1-oxopropyl)-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 653600-90-9 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane-3-carboxylic acid, 9-(phenylmethyl)-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/512,559



REFERENCE COUNT:


3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


~~LI~~ ANSWER 5 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2003:950110 CAPLUS  
 DOCUMENT NUMBER: 140:16752  
 TITLE: Preparation of diazabicyclic central nervous system (CNS) active agents for use in pharmaceutical compositions  
 INVENTOR(S): Bunnelle, William H.; Cristina, Daniela Barlocco; Daanen, Jerome F.; Dart, Michael J.; Meyer, Michael D.; Ryther, Keith B.; Schrimpf, Michael R.; Sippy, Kevin B.; Toupence, Richard B.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont. of U.S. Ser. No. 466,719.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003225268	A1	20031204	US 2003-412510	20030411
PRIORITY APPLN. INFO.:			US 1999-117807P	P 19990129
			US 1999-466719	A1 19991217

OTHER SOURCE(S): MARPAT 140:16752  
 GI



I



II

AB Diazabicyclic compds., such as I [V and X = bond or CH<sub>2</sub>; W and Y = bond, CH<sub>2</sub>, or CH<sub>2</sub>CH<sub>2</sub>; Z = CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, or CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>; L1 = a bond or (CH<sub>2</sub>)<sub>n</sub>; n = 1-5; R1 = heteroarom. rings, such as pyridinyl, pyrimidinyl, pyrazinyl, quinolinyl, etc.; R2 = H, alkoxy carbonyl, (amino)alkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy(alkyl), phenoxycarbonyl, or NH<sub>2</sub>], were prepared for therapeutic use controlling synaptic transmission in mammals. These diazabicycles are claimed for use in the treatment of Alzheimer's disease, Parkinson's disease, memory dysfunction, Tourette's syndrome, sleep disorders, attention deficit hyperactivity disorder, neurodegeneration, inflammation, neuroprotection, amyotrophic lateral sclerosis, anxiety, depression, mania, schizophrenia, anorexia and other eating disorders, AIDS-induced dementia, epilepsy, urinary incontinence, Crohn's disease, migraines, premenstrual syndrome, erectile dysfunction, substance abuse, smoking cessation, and inflammatory bowel syndrome. Thus, (1S,4S)-2-(6-chloro-3-pyridinyl)-2,5-diazabicyclo[2.2.1]heptane II (R = H) was prepared via a reaction of tert-Bu (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate with 2-chloro-5-iodopyridine using tert-BuONa, Pd<sub>2</sub>(dba)<sub>3</sub> and BINAP in toluene to give the BOC-protected intermediate II (R = CO<sub>2</sub>CMe<sub>3</sub>) in 58% yield and subsequent N-deprotection of II (R = CO<sub>2</sub>CMe<sub>3</sub>) using 4N HCl/dioxane to form II (R = H) in 77% yield. The prepared diazabicycles were assayed for nicotinic acetylcholine receptor binding potency in synaptic membrane prepns. from whole rat brain and were

10/512,559

tested for their effectiveness of nicotinic acetylcholine receptor ligands as analgesic agents in the mouse hot plate paradigm.


IT 286947-15-7P, tert-Butyl 9-methyl-3,9-diazabicyclo[4.2.1]nonane-3-carboxylate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of diazabicyclic central nervous system active agents for use in pharmaceutical compns. which selectively control neurotransmitter release)

RN 286947-15-7 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane-3-carboxylic acid, 9-methyl-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



~~LI~~ ANSWER 6 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:289209 CAPLUS

DOCUMENT NUMBER: 137:195439

TITLE: Studies of the biogenic amine transporters. 10.  
Characterization of a novel cocaine binding site in  
brain membranes prepared from dopamine transporter  
knockout mice

AUTHOR(S): Rothman, Richard B.; Carroll, F. Ivy; Morales,  
Marisela; Rowley, Daniel L.; Rice, Kenner C.; Dersch,  
Christina M.; Donovan, David M.

CORPORATE SOURCE: IRP, NIDA, NIH, Baltimore, MD, 21224, USA

SOURCE: Synapse (New York, NY, United States) (2002), 44(2),  
94-105

CODEN: SYNAET; ISSN: 0887-4476

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Previous work suggested that the cocaine analog [125I]RTI-55 labels a novel binding site in rat brain membranes, which is not associated with the dopamine (DA), serotonin (5-HT), or norepinephrine (NE) transporters. Here, we tested whether this site is a product of the DA transporter (DAT) gene. We used a T-antigen knock-in at the DAT gene that results in an effective DAT knock-out (KO) confirmed by Southern blot, DAT immunohistochem., and [125I]RTI-55 ligand binding. Brain membranes were prepared from frozen whole brain minus caudate of wild-type (WT) B6/Sv 129, +/- and -/- (KO) mice. KO mice were used at approx. 23 days of age. Binding surface anal. of [125I]RTI-55 binding to membranes prepared from the brains of WT mice, with 100 nM citalopram to block binding to the 5-HT transporter (SERT), revealed two binding sites: the DAT and a second site, replicating previous studies conducted with rat brains. In the absence of the DAT (-/- mice), binding surface anal. demonstrated that [125I]RTI-55 labeled two sites: the NET and a second site called site "X". Structure-activity studies of site "X" demonstrated that high-affinity ligands for the DAT, NET, and SERT have low or negligible affinity for site "X". The relatively high d. of site "X" in brain membranes and the fact that the Ki values of cocaine and cocaethylene for site "X" are in the range achieved in the brain following cocaine administration suggests that site "X" could contribute to the pharmacol. or toxicol. effects of cocaine. Further progress in delineating the function of site "X" will depend on developing potent and selective agents for this site.


IT 321365-92-8

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(novel cocaine binding site in brain membranes prepared from dopamine transporter knockout mice)

RN 321365-92-8 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[2-[bis(4-fluorophenyl)methoxy]ethyl]-9-methyl- (9CI) (CA INDEX NAME)

10/512,559



REFERENCE COUNT:

15

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~1~~ ANSWER 7 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:31453 CAPLUS

DOCUMENT NUMBER: 136:85836

TITLE: Aryl- and heteroaryl-substituted diazabicycloalkanes as cholinergic ligands for the nicotinic acetylcholine receptor

INVENTOR(S): Peters, Dan; Olsen, Gunnar M.; Nielsen, Elsebet  
Ostergaard; Ahning, Philip K.; Nielsen, Simon  
Feldbaek; Jorgensen, Tino Dyhring

PATENT ASSIGNEE(S): Neurosearch A/S, Den.

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002564	A1	20020110	WO 2001-DK432	20010620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2410945	A1	20020110	CA 2001-2410945	20010620
EP 1301514	A1	20030416	EP 2001-943186	20010620
EP 1301514	B1	20050126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004502692	T	20040129	JP 2002-507816	20010620
AT 287888	T	20050215	AT 2001-943186	20010620
NZ 522793	A	20050225	NZ 2001-522793	20010620
US 2003176416	A1	20030918	US 2002-276160	20021113
US 7060699	B2	20060613		
HK 1057550	A1	20050520	HK 2004-100323	20040115
PRIORITY APPLN. INFO.:			DK 2000-1037	A 20000704
			WO 2000-PA1037	A 20000704
			WO 2001-DK432	W 20010620

OTHER SOURCE(S): MARPAT 136:85836

GI



AB Title compds. I [one of R and R1 = H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, monocyclic or polycyclic aryl, aralkyl and the other = 1 (un)substituted monocyclic or polycyclic aryl; n = 2, 3; m = 1, 2, 3] and their dimers were prepared for use as cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Thus, 9-methyl-3,9-diazabicyclo[4.2.1]nonane was treated with 2-chloroquinoline to give the 3-(2-quinolinyl) derivative which had an IC50 for inhibition of noradrenaline uptake at rat brain serotonin transporters of 0.013  $\mu$ M. Due to their pharmacol. profile I may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.


IT 387870-06-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aryl- and heteroaryl-substituted diazabicycloalkanes as cholinergic ligands for the nicotinic acetylcholine receptor)

RN 387870-06-6 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-acetyl-9-(phenylmethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~LI~~ ANSWER 8 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:811122 CAPLUS  
 DOCUMENT NUMBER: 134:115932  
 TITLE: Synthesis and Transporter Binding Properties of  
 Bridged Piperazine Analogues of 1-{2-[Bis(4-  
 fluorophenyl)methoxy]ethyl}-4-(3-  
 phenylpropyl)piperazine (GBR 12909)  
 AUTHOR(S): Zhang, Ying; Rothman, Richard B.; Dersch, Christina  
 M.; de Costa, Brian R.; Jacobson, Arthur E.; Rice,  
 Kenner C.  
 CORPORATE SOURCE: Laboratory of Medicinal Chemistry, National Institute  
 of Diabetes and Digestive and Kidney Diseases National  
 Institutes of Health, Bethesda, MD, 20892-0815, USA  
 SOURCE: Journal of Medicinal Chemistry (2000), 43(25),  
 4840-4849  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 134:115932  
 GI



AB A series of bridged piperazines, e.g. I [R = Me (II), 3-phenylpropyl  
 (III), indol-2-ylmethyl (IV), etc.], was prepared and evaluated for their  
 ability to bind dopamine transporter (DAT) and to inhibit the uptake of  
 3H-labeled dopamine (DA). The binding data indicated that II and III  
 showed high affinity for the DAT (IC<sub>50</sub> = 8.0 and 8.2 nM, resp.), and II  
 had high selectivity at the DAT relative to the serotonin transporter  
 (SERT) (88- and 93-fold for binding and reuptake, resp.). II and III also  
 displayed linear activity in DA uptake inhibition, having similar binding  
 and reuptake inhibition profile to the title non-bridged analog (GBR  
 12909). Compound IV showed the highest affinity (IC<sub>50</sub> = 1.4 nM) in the  
 series, with a 6-fold increase over III. Interestingly, IV exhibited a  
 high ratio (29-fold) of IC<sub>50</sub> for the inhibition of DA reuptake vs. binding  
 to the DAT.


IT 321366-09-0P 321366-10-3P 321366-12-5P  
 321366-13-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
 study); PREP (Preparation)  
 (preparation and dopamine transporter binding properties of bridged  
 piperazines)

RN 321366-09-0 CAPLUS

10/512,559


CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[2-(diphenylmethoxy)ethyl]-9-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 321366-10-3 CAPLUS


CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[2-[bis(4-fluorophenyl)methoxy]ethyl]-9-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 321366-12-5 CAPLUS


CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[2-(diphenylmethoxy)ethyl]-9-(3-phenylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 321366-13-6 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[2-[bis(4-fluorophenyl)methoxy]ethyl]-9-(3-phenylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

IT 321365-91-7P 321365-92-8P 321365-95-1P  
321365-96-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and dopamine transporter binding properties of bridged  
piperazines)


RN 321365-91-7 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[2-(diphenylmethoxy)ethyl]-9-methyl-  
(9CI) (CA INDEX NAME)



RN 321365-92-8 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[2-[bis(4-fluorophenyl)methoxy]ethyl]-9-  
methyl- (9CI) (CA INDEX NAME)




RN 321365-95-1 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[2-(diphenylmethoxy)ethyl]-9-(3-


10/512,559

phenylpropyl)- (9CI) (CA INDEX NAME)



RN 321365-96-2 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[2-[bis(4-fluorophenyl)methoxy]ethyl]-9-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

56

THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

X ANSWER 9 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:790504 CAPLUS  
 DOCUMENT NUMBER: 133:350254  
 TITLE: Heteroaryl diazabicycloalkanes and their affinity for  
 nicotinic acetylcholine receptors  
 INVENTOR(S): Peters, Dan; Nielsen, Simon Feldbaek; Olsen, Gunnar  
 M.; Nielsen, Elsebet Ostergaard  
 PATENT ASSIGNEE(S): Neurosearch A/S, Den.  
 SOURCE: PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066586	A1	20001109	WO 2000-DK211	20000427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2365258	A1	20001109	CA 2000-2365258	20000427
EP 1177196	A1	20020206	EP 2000-922470	20000427
EP 1177196	B1	20040310		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002543201	T	20021217	JP 2000-615616	20000427
NZ 513575	A	20030725	NZ 2000-513575	20000427
AT 261448	T	20040315	AT 2000-922470	20000427
AU 774867	B2	20040708	AU 2000-42858	20000427
US 2002037893	A1	20020328	US 2001-933944	20010822
US 6552012	B2	20030422		
PRIORITY APPLN. INFO.:			DK 1999-602	A 19990504
			WO 2000-DK211	W 20000427
OTHER SOURCE(S):			MARPAT 133:350254	
GI				



AB Title compds. I ( $m = 1, 2, 3$ ;  $n = 2, 3$ ; one of R and R1 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, etc., and the other of R and R1 = heterocyclyl) were prepared for treatment of disorders involving nicotinic acetylcholine receptors. Thus, a mixture of 3.6 mmol 9-methyl-3,9-diazabicyclo[4.2.1]nonane, 3.6 mmol 3,6-dichloropyridazine, and 20 mL toluene was stirred at reflux for 2.5 h and the product treated with a 9:1 Et2O-MeOH mixture saturated with fumaric acid to give a 24% yield of

3-(6-chloro-3-pyridazinyl)-9-methyl-3,9-diazabicyclo[4.2.1]nonane fumaric acid salt. The affinities of I for nicotinic acetylcholine receptors were determined in tests for in vitro inhibition of 3H-epibatidin, 3H- $\alpha$ -bungarotoxin, and 3H-cytisine binding.


IT 286947-15-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(heteroaryl diazabicycloalkanes and their affinity for nicotinic acetylcholine receptors)

RN 286947-15-7 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane-3-carboxylic acid, 9-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~1~~ ANSWER 10 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:535147 CAPLUS

DOCUMENT NUMBER: 133:135332

TITLE: Preparation of diazabicyclic derivatives as nicotinic acetylcholine receptor ligands

INVENTOR(S): Bunnelle, William H.; Cristina, Daniela Barlocco; Daanen, Jerome F.; Dart, Michael J.; Meyer, Michael D.; Ryther, Keith B.; Schrimpf, Michael R.; Sippy, Kevin B.; Toupence, Richard B.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044755	A1	20000803	WO 2000-US1620	20000125
W:			AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW	
RW:			GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
CA 2361525	A1	20000803	CA 2000-2361525	20000125
EP 1147112	A1	20011024	EP 2000-906998	20000125
EP 1147112	B1	20031029		
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO	
TR 200102162	T2	20011221	TR 2001-2162	20000125
BR 2000007664	A	20020507	BR 2000-7664	20000125
HU 200200332	A2	20020629	HU 2002-332	20000125
JP 2002535409	T	20021022	JP 2000-596011	20000125
EP 1359152	A2	20031105	EP 2003-17562	20000125
EP 1359152	A3	20031217		
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY	
AT 253067	T	20031115	AT 2000-906998	20000125
NZ 512884	A	20040326	NZ 2000-512884	20000125
PT 1147112	T	20040331	PT 2000-906998	20000125
AU 773795	B2	20040603	AU 2000-28569	20000125
ES 2209825	T3	20040701	ES 2000-906998	20000125
CN 1636996	A	20050713	CN 2004-10097482	20000125
ZA 2001005835	A	20021016	ZA 2001-5835	20010716
NO 2001003731	A	20010918	NO 2001-3731	20010730
BG 105836	A	20020329	BG 2001-105836	20010822
HK 1043116	A1	20041015	HK 2002-102948	20020418
PRIORITY APPLN. INFO.:			US 1999-239838	A 19990129
			EP 2000-906998	A3 20000125
			WO 2000-US1620	W 20000125
OTHER SOURCE(S):		MARPAT 133:135332		
GI				



I



II

AB The title compds. (I) [wherein V and X = independently a bond or CH<sub>2</sub>; W and Y = independently a bond, CH<sub>2</sub>, or CH<sub>2</sub>CH<sub>2</sub>; Z = CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, or CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>; L<sub>1</sub> = a bond or (CH<sub>2</sub>)<sub>n</sub>; n = 1-5; R<sub>1</sub> = certain heteroarom. rings, such as pyridinyl, pyrimidinyl, pyrazinyl, quinolinyl, etc.; R<sub>2</sub> = H, alkoxy carbonyl, (amino)alkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy(alkyl), phenoxycarbonyl, or NH<sub>2</sub>] and their pharmaceutically acceptable salts were prepared as cholinergic modulators for the treatment of pain and other conditions. For example, (-)-II•Ts-OH was prepared in a multi-step sequence involving N-protection of (1R,4R)-2-benzyl-2,5-diazabicyclo[2.2.1]heptane•2HBr with CO(OBu-t)<sub>2</sub> (94%), debenzylation (93%), addition of 2-chloro-5-iodopyridine (67%), and deprotection followed by salt formation (71%). (-)-II•Ts-OH exhibited high affinity for the nicotinic acetylcholine receptor with K<sub>i</sub> of 0.01 nM and showed a significant antinociceptive effect at the minimally ED of 0.62 μmol/kg in the mouse hot plate paradigm.


IT 286947-15-7P, tert-Butyl 9-methyl-3,9-diazabicyclo[4.2.1]nonane-3-carboxylate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-substituted diazabicycloalkanes as nicotinic acetylcholine receptor ligands by addition of haloheterocycles to protected diazabicycloalkanes followed by deprotection and optional substitution)

RN 286947-15-7 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane-3-carboxylic acid, 9-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:


4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/512,559

~~LI~~ ANSWER 11 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2000:68456 CAPLUS  
DOCUMENT NUMBER: 132:107945  
TITLE: Preparation of 9-trimethoxyphenyloxalyl-2-oxo-3,9-diaza[3.3.1]nonanes and analogs as FKBP rotamase inhibitors  
INVENTOR(S): Katoh, Susumu; Kawakami, Hiroshi; Tada, Hiroki; Linton, Maria Angelica; Kalish, Vincent; Tatlock, John Howard; Villafranca, J. Ernest  
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 130 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004020	A1	20000127	WO 1999-US15965	19990715
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2337377	A1	20000127	CA 1999-2337377	19990715
AU 9949963	A	20000207	AU 1999-49963	19990715
AU 756912	B2	20030123		
EP 1098897	A1	20010516	EP 1999-934043	19990715
EP 1098897	B1	20040609		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9912423	A	20010605	BR 1999-12423	19990715
TR 200100122	T2	20010821	TR 2001-200100122	19990715
SI 20638	A	20020228	SI 1999-20067	19990715
EE 200100032	A	20020617	EE 2001-32	19990715
JP 2002520413	T	20020709	JP 2000-560126	19990715
HU 200200637	A2	20020828	HU 2002-637	19990715
NZ 509211	A	20021025	NZ 1999-509211	19990715
AT 268772	T	20040615	AT 1999-934043	19990715
PT 1098897	T	20041029	PT 1999-934043	19990715
ES 2226409	T3	20050316	ES 1999-934043	19990715
US 6630472	B1	20031007	US 1999-356240	19990716
ZA 2001000320	A	20020711	ZA 2001-320	20010111
IN 2001MN00041	A	20050304	IN 2001-MN41	20010111
NO 2001000191	A	20010316	NO 2001-191	20010112
LT 4850	B	20011025	LT 2001-12	20010215
BG 105268	A	20011130	BG 2001-105268	20010216
HR 2001000118	A1	20020228	HR 2001-118	20010216
LV 12665	B	20011120	LV 2001-23	20010313
PRIORITY APPLN. INFO.:			US 1998-93299P	P 19980717
			US 1999-132884P	P 19990506
			WO 1999-US15965	W 19990715
OTHER SOURCE(S):	MARPAT 132:107945			
GI				




AB Title compds. [I; R = COCOR<sub>1</sub>; R<sub>1</sub> = H, (cyclo)alk(en)yl, aryl, etc.; R<sub>2</sub> = H, (ar)alkyl, alkoxy(alkyl), alkanoyloxy(alkyl), etc.; R<sub>3</sub> = H, cyano, alkoxy, etc.; R<sub>2</sub>R<sub>3</sub> = atoms to complete a ring] were prepared. Thus, piperidine-2,6-dicarboxylic acid was N-protected and the product treated with Ac<sub>2</sub>O to give the anhydride which was cyclocondensed with PhCH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub> to give, in 3 addnl. steps, I (R<sub>2</sub> = CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>Ph, R<sub>3</sub> = H) (II; R = H) which was N-acylated by 3,4,5-(MeO)<sub>3</sub>C<sub>6</sub>H<sub>2</sub>COCO<sub>2</sub>H to give II [R = COCOC<sub>6</sub>H<sub>2</sub>(OMe)<sub>3</sub>-3,4,5]. Data for biol. activity of I were given.

IT 255910-70-4P 255910-71-5P 255910-72-6P  
255910-76-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 9-trimethoxyphenyloxalyl-2-oxo-3,9-diaza[3.3.1]nonanes and analogs as FKBP rotamase inhibitors)


RN 255910-70-4 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decan-2-one, 10-[oxo(3,4,5-trimethoxyphenyl)acetyl]-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 255910-71-5 CAPLUS


CN 3,10-Diazabicyclo[4.3.1]decan-2-one, 10-[oxo(3,4,5-trimethoxyphenyl)acetyl]-3-(4-phenylbutyl)- (9CI) (CA INDEX NAME)



RN 255910-72-6 CAPLUS



10/512,559

CN 3,10-Diazabicyclo[4.3.1]decan-2-one, 10-(3,3-dimethyl-1,2-dioxopentyl)-3-(4-phenylbutyl)- (9CI) (CA INDEX NAME)



RN 255910-76-0 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decan-2-one, 10-(10-azabicyclo[4.3.1]dec-10-yloxoacetyl)-3-(4-phenylbutyl)- (9CI) (CA INDEX NAME)




IT 255910-96-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 9-trimethoxyphenyloxalyl-2-oxo-3,9-diaza[3.3.1]nonanes and analogs as FKBP rotamase inhibitors)

RN 255910-96-4 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decane-10-carboxylic acid, 2-oxo-3-(2-phenylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/512,559

ANSWER 12 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1988:492845 CAPLUS

DOCUMENT NUMBER: 109:92845

TITLE: Studies on azabicyclo systems. Syntheses and spasmolytic activity of analogs of 9-methyl-3,9-diazabicyclo[4.2.1]nonane and 10-methyl-3,10-diazabicyclo[4.3.1]decane

AUTHOR(S): Razdan, Balkishen; Sharma, Ashok K.; Kumari, Kanya; Bodla, Ramesh B.; Gupta, Bharat L.; Patnaik, Gyanendra K.

CORPORATE SOURCE: Dep. Pharm. Sci., Birla Inst. Technol., Mesra, 835215, India

SOURCE: European Journal of Medicinal Chemistry (1987), 22(6), 573-7


CODEN: EJMCA5; ISSN: 0223-5234

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 109:92845

GI



AB Diazabicyclo compds. I ( $n = 1, 2$ ;  $x = H_2$ ,  $R = H$ ) were prepared and converted to amides, e.g., I [ $n = 1, 2$ ;  $x = H_2$ ,  $R = COR_1$ ;  $R_1 = Me, CH_2Cl, Et, Pr, Ph$ , substituted  $Ph, CH_2CH_2Cl, (CH_2)_mNR_2R_3$ ;  $m = 2, 3$ ;  $R_2 = H, R_3 = Et, Ph, 2-MeC_6H_4, 4-MeC_6H_4$ ;  $NR_2R_3 = piperidino, morpholino$ ] and sulfonamides I [ $n = 1, 2$ ,  $X = H, R = SO_2R_4$ ;  $R_4 = Ph, 4-MeC_6H_4, 4-H_2NC_6H_4$ ]. All the compds. prepared and I ( $n = 1, 2$ ;  $X = O, R = H$ ) were tested for spasmolytic activity. I ( $n = 1, X = H_2, R = H$ ; II) showed specific anti-serotonin activity. Amides of II with aromatic acids showed antihistaminic properties whereas amides of I ( $n = 2, X = H_2, R = H$ ) with aliphatic acids showed spasmogenic activity. A number of amides and sulfonamides showed non-specific spasmolytic activity.

IT 115748-53-3P 115748-54-4P 115748-55-5P  
115748-56-6P 115748-57-7P 115748-58-8P  
115748-59-9P 115748-60-2P 115748-61-3P  
115748-62-4P 115748-63-5P 115748-64-6P  
115748-65-7P 115748-66-8P 115748-68-0P  
115748-69-1P 115748-70-4P 115748-72-6P  
115748-74-8P 115748-75-9P 115748-76-0P  
115748-78-2P 115748-79-3P 115748-80-6P  
115748-82-8P 115748-83-9P 115748-85-1P  
115748-86-2P 115748-97-5P 115748-98-6P  
115748-99-7P 115749-00-3P 115749-01-4P  
115749-02-5P 115749-03-6P 115749-04-7P  
115749-05-8P 115749-06-9P 115749-07-0P  
115749-08-1P 115749-09-2P 115749-10-5P  
115749-11-6P 115791-76-9P 115791-77-0P  
115791-78-1P


RL: SPN (Synthetic preparation); PREP (Preparation)

10/512,559

(preparation and spasmolytic activity of)

RN 115748-53-3 CAPLUS


CN 3,10-Diazabicyclo[4.3.1]decane, 3-acetyl-10-methyl-, monohydrochloride  
(9CI) (CA INDEX NAME)



● HCl

RN 115748-54-4 CAPLUS


CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(chloroacetyl)-9-methyl-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 115748-55-5 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decane, 3-(chloroacetyl)-10-methyl-,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 115748-56-6 CAPLUS


CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-(1-oxopropyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)

10/512,559




● HCl

RN 115748-57-7 CAPLUS  
CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(3-chloro-1-oxopropyl)-9-methyl-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 115748-58-8 CAPLUS  
CN 3,9-Diazabicyclo[4.2.1]nonane, 3-benzoyl-9-methyl-, monohydrochloride  
(9CI) (CA INDEX NAME)



● HCl


RN 115748-59-9 CAPLUS  
CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-(4-methylbenzoyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)

10/512,559




● HCl

RN 115748-60-2 CAPLUS  
CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-(4-methylbenzoyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 115748-61-3 CAPLUS  
CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-(2-nitrobenzoyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 115748-62-4 CAPLUS  
CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-(3-nitrobenzoyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 115748-63-5 CAPLUS  
CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-(4-nitrobenzoyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 115748-64-6 CAPLUS  
CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(3,5-dinitrobenzoyl)-9-methyl-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 115748-65-7 CAPLUS  
CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[(ethylamino)acetyl]-9-methyl-,  
dihydrochloride (9CI) (CA INDEX NAME)


10/512,559



●2 HCl

RN 115748-66-8 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-(1-piperidinylacetyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 115748-68-0 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[1-oxo-3-(1-piperidinyl)propyl]-, compd. with 2,4,6-trinitrophenol (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 115748-67-9

CMF C16 H29 N3 O




CM 2

CRN 88-89-1


CMF C6 H3 N3 O7

10/512,559




RN 115748-69-1 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-[1-oxo-3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 115748-70-4 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-(4-morpholinylacetyl)- (9CI)  
(CA INDEX NAME)




RN 115748-72-6 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[3-(4-morpholinyl)-1-oxopropyl]-  
, compd. with 2,4,6-trinitrophenol (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 115748-71-5

CMF C15 H27 N3 O2




CM 2

CRN 88-89-1

CMF C6 H3 N3 O7


10/512,559



RN 115748-74-8 CAPLUS  
CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-(4-morpholinylacetyl)-, compd.  
with 2,4,6-trinitrophenol (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 115748-73-7  
CMF C15 H27 N3 O2




CM 2

CRN 88-89-1  
CMF C6 H3 N3 O7



RN 115748-75-9 CAPLUS  
CN 3-Aza-10-azoniabicyclo[4.3.1]decane, 10-ethyl-3-[3-(4-ethylmorpholinium-4-yl)-1-oxopropyl]-10-methyl-, diiodide (9CI) (CA INDEX NAME)




● 2 I<sup>-</sup>

RN 115748-76-0 CAPLUS

10/512,559

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[(phenylamino)acetyl]- (9CI)  
(CA INDEX NAME)




RN 115748-78-2 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[1-oxo-3-(phenylamino)propyl]-,  
compd. with 2,4,6-trinitrophenol (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 115748-77-1


CMF C17 H25 N3 O



CM 2


CRN 88-89-1

CMF C6 H3 N3 O7




RN 115748-79-3 CAPLUS

CN 3-Aza-10-azoniabicyclo[4.3.1]decane, 10-ethyl-10-methyl-3-[1-oxo-3-(phenylamino)propyl]-, iodide (9CI) (CA INDEX NAME)



RN 115748-80-6 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[[ (2-methylphenyl) amino] acetyl]- (9CI) (CA INDEX NAME)




RN 115748-82-8 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[3-[(2-methylphenyl) amino]-1-oxopropyl]-, compd. with 2,4,6-trinitrophenol (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 115748-81-7


CMF C18 H27 N3 O



CM 2

CRN 88-89-1


CMF C6 H3 N3 O7



10/512,559

RN 115748-83-9 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-[[ (4-methylphenyl)amino]acetyl]- (9CI) (CA INDEX NAME)




RN 115748-85-1 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[3-[(4-methylphenyl)amino]-1-oxopropyl]-, compd. with 2,4,6-trinitrophenol (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 115748-84-0


CMF C18 H27 N3 O



CM 2


CRN 88-89-1

CMF C6 H3 N3 O7




RN 115748-86-2 CAPLUS


CN 3-Aza-10-azoniabicyclo[4.3.1]decane, 10-ethyl-10-methyl-3-[3-[(4-methylphenyl)amino]-1-oxopropyl]-, iodide (9CI) (CA INDEX NAME)




RN 115748-97-5 CAPLUS  
CN 3,10-Diazabicyclo[4.3.1]decane, 3-acetyl-10-methyl- (9CI) (CA INDEX NAME)



RN 115748-98-6 CAPLUS  
CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(chloroacetyl)-9-methyl- (9CI) (CA INDEX NAME)




RN 115748-99-7 CAPLUS  
CN 3,10-Diazabicyclo[4.3.1]decane, 3-(chloroacetyl)-10-methyl- (9CI) (CA INDEX NAME)




RN 115749-00-3 CAPLUS  
CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-(1-oxopropyl)- (9CI) (CA INDEX NAME)

10/512,559




RN 115749-01-4 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(3-chloro-1-oxopropyl)-9-methyl- (9CI)  
(CA INDEX NAME)




RN 115749-02-5 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decane, 3-(3-chloro-1-oxopropyl)-10-methyl- (9CI)  
(CA INDEX NAME)




RN 115749-03-6 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-(1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 115749-04-7 CAPLUS


CN 3,9-Diazabicyclo[4.2.1]nonane, 3-benzoyl-9-methyl- (9CI) (CA INDEX NAME)



10/512,559


RN 115749-05-8 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decane, 3-benzoyl-10-methyl- (9CI) (CA INDEX NAME)




RN 115749-06-9 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)




RN 115749-07-0 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 115749-08-1 CAPLUS


CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-(2-nitrobenzoyl)- (9CI) (CA INDEX NAME)



RN 115749-09-2 CAPLUS


CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-(3-nitrobenzoyl)- (9CI) (CA INDEX NAME)

10/512,559




RN 115749-10-5 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-(4-nitrobenzoyl)- (9CI) (CA INDEX NAME)




RN 115749-11-6 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(3,5-dinitrobenzoyl)-9-methyl- (9CI) (CA INDEX NAME)



RN 115791-76-9 CAPLUS


CN 3,10-Diazabicyclo[4.3.1]decane, 3-(3-chloro-1-oxopropyl)-10-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 115791-77-0 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-(1-oxobutyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 115791-78-1 CAPLUS  
 CN 3,10-Diazabicyclo[4.3.1]decane, 3-benzoyl-10-methyl-, monohydrochloride  
 (9CI) (CA INDEX NAME)




● HCl

IT 115748-67-9P 115748-71-5P 115748-73-7P  
 115748-77-1P 115748-81-7P 115748-84-0P  
 115748-93-1P 115748-94-2P 115748-95-3P  
 115748-96-4P 115791-79-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 115748-67-9 CAPLUS  
 CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[1-oxo-3-(1-piperidinyl)propyl]-  
 (9CI) (CA INDEX NAME)




RN 115748-71-5 CAPLUS  
 CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[3-(4-morpholinyl)-1-oxopropyl]-  
 (9CI) (CA INDEX NAME)



10/512,559


RN 115748-73-7 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-(4-morpholinylacetyl)- (9CI)  
(CA INDEX NAME)




RN 115748-77-1 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[1-oxo-3-(phenylamino)propyl]-  
(9CI) (CA INDEX NAME)




RN 115748-81-7 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[3-[(2-methylphenyl)amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 115748-84-0 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-[3-[(4-methylphenyl)amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 115748-93-1 CAPLUS


CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[(ethylamino)acetyl]-9-methyl- (9CI) (CA INDEX NAME)




RN 115748-94-2 CAPLUS  
 CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-(1-piperidinylacetyl)- (9CI)  
 (CA INDEX NAME)




RN 115748-95-3 CAPLUS  
 CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-[1-oxo-3-(phenylamino)propyl]-  
 (9CI) (CA INDEX NAME)



RN 115748-96-4 CAPLUS  
 CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-[3-[(4-methylphenyl)amino]-1-  
 oxopropyl]- (9CI) (CA INDEX NAME)



RN 115791-79-2 CAPLUS  
 CN 3,10-Diazabicyclo[4.3.1]decane, 10-methyl-3-[3-(4-morpholinyl)-1-  
 oxopropyl]- (9CI) (CA INDEX NAME)



10/512,559

~~INN~~ ANSWER 13 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1977:89650 CAPLUS

DOCUMENT NUMBER: 86:89650

TITLE: Photoreactions. 47. Internal photocyclization of bis(1,2-dihydroisoquinolines) and a methylenebis(naphthalenone)

AUTHOR(S): Nakamura, Yushin; Zsindely, Janos; Schmid, Hans

CORPORATE SOURCE: Org.-Chem. Inst., Univ. Zurich, Zurich, Switz.

SOURCE: Heterocycles (1976), 5(1), 427-43

CODEN: HTCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal

LANGUAGE: German

GI For diagram(s), see printed CA Issue.


AB The racemic isoquinoline dimers I (R = H, Me) underwent photocycloaddn. to give II (R = H, Me, R1 = Ac), which were reduced with (Me<sub>2</sub>CHCH<sub>2</sub>)<sub>2</sub>AlH<sub>2</sub> to give II (R1 = Et). Meso-I similarly gave III, together with II (R = Me, R1 = AC). The naphthalenone dimer IV similarly gave V.

IT 61876-92-4P 61876-98-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reduction of)


RN 61876-92-4 CAPLUS

CN 6,11,13-(Iminometheno)-5H-dibenzo[a,e]cyclononen-5,12-imine,  
15,16-diacetyl-6,11,12,13-tetrahydro- (9CI) (CA INDEX NAME)



RN 61876-98-0 CAPLUS

CN 6,11,13-(Iminometheno)-5H-dibenzo[a,e]cyclononen-5,12-imine,  
15,16-diacetyl-6,11,12,13-tetrahydro-12,14-dimethyl- (9CI) (CA INDEX NAME)



IT 61876-93-5P 61876-99-1P


RL: SPN (Synthetic preparation); PREP (Preparation)

10/512,559

(preparation of)


RN 61876-93-5 CAPLUS

CN 6,11,13-(Iminometheno)-5H-dibenzo[a,e]cyclononen-5,12-imine,  
15,16-diethyl-6,11,12,13-tetrahydro- (9CI) (CA INDEX NAME)



10/512,559

~~LI~~ ANSWER 14 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1972:461757 CAPLUS  
DOCUMENT NUMBER: 77:61757  
TITLE: Alkylation, acylation, and reduction studies on  
1-cyano-1,2-dihydro- and -1,2,3,4-  
tetrahydroisoquinoline derivatives  
AUTHOR(S): Boehme, Horst; Stoecker, Klaus Peter  
CORPORATE SOURCE: Pharm.-Chem. Inst., Univ. Marburg, Marburg/L., Fed.  
Rep. Ger.  
SOURCE: Chemische Berichte (1972), 105(5), 1578-85  
CODEN: CHBEAM; ISSN: 0009-2940  
DOCUMENT TYPE: Journal  
LANGUAGE: German  
GI For diagram(s), see printed CA Issue.  
AB Successive treatment of 2-benzoyl-1-cyano-1,2,3,4-tetrahydroisoquinoline  
(I) with NaH in DMF and with alkyl or acyl halides gave the corresponding  
1-alkyl- or 1-acyl-1-cyano-1,2,3,4-tetrahydroisoquinolines (II), resp.  
Thioacylation and cyanoethylation of I with PhNCS and CH<sub>2</sub>:CHCN, resp.,  
also took place in 1-position. Reduction of 2-alkyl-1-cyano-1,2-  
dihydroisoquinolines with LiAlH<sub>4</sub> gave 2-alkyl-1,2-dihydro-isoquinolines  
(III).  
IT 37039-55-7P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 37039-55-7 CAPLUS  
CN 12,5,7-(Iminometheno)benzo[b]phenanthridine-5(6H)-carbonitrile,  
6a,7,12,12a-tetrahydro-6,13-dimethyl- (9CI) (CA INDEX NAME)



10/512,559

~~LI~~ ANSWER 15 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1971:488799 CAPLUS

DOCUMENT NUMBER: 75:88799

TITLE: Synthesis and some conformational observations on the 3,10-diazabicyclo[4.3.1]decane system

AUTHOR(S): Sasaki, Tadashi; Eguchi, Shoji; Kiriya, Tsutomu

CORPORATE SOURCE: Fac. Eng., Nagoya Univ., Nagoya, Japan

SOURCE: Journal of Organic Chemistry (1971), 36(15), 2061-5

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB 10-Methyl-3,10-diazabicyclo[4.3.1]decane (I) and its 7,9-exo-ethano derivative were prepared by  $\text{LiAlH}_4$  reduction of 10-methyl-3,10-diazabicyclo[4.3.1]decan-4-one (II) and its 7,9-cxo-ethano derivative (III), both of which were obtained by the Schmidt reaction of pseudopelletierine (IV) and 6,8-exo-ethanopseudopelletierine (V), resp. The same reduction of II afforded 76% stable Al complex, tris(10-methyl-3,10-diazabicyclo[4.3.1]decane)aluminum hydroxide, but reduction of III yielded no such stable complex. Treatment of I with 1 equivalent of methylene iodide gave 10-methyl-3,10-diazatricyclo[4.3.1.13,10]undecanium iodide (19).

IT 29577-65-9P 29584-56-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 29577-65-9 CAPLUS


CN 8,11-Diazatricyclo[4.4.1.12,5]dodecane, 8,11-dimethyl-, monohydriodide, stereoisomer (8CI) (CA INDEX NAME)



● HI

RN 29584-56-3 CAPLUS

CN 3-Aza-10-azoniabicyclo[4.3.1]decane, 3,10,10-trimethyl-, iodide (8CI) (CA INDEX NAME)



● I<sup>-</sup>

~~1/1~~ ANSWER 16 OF 20 .CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1970:43499 CAPLUS  
 DOCUMENT NUMBER: 72:43499  
 TITLE: Tranquilizing N-(aroylalkyl)azabicycloalkanes  
 PATENT ASSIGNEE(S): CIBA Ltd.  
 SOURCE: Fr., 20 pp.  
 CODEN: FRXXAK  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1549235		19681213	FR	19670720
CH 486463			CH	
CH 508626			CH	
DE 1670448			DE	
FR 7320			FR	
GB 1195729			GB	
PRIORITY APPLN. INFO.:			CH	19660727
			CH	19670606

OTHER SOURCE(S): MARPAT 72:43499

GI For diagram(s), see printed CA Issue.

AB The title compds. I or II were prepared To 20 g 3-azabicyclo[3.2.2]nonane (III), 50.4 g Na<sub>2</sub>CO<sub>3</sub> and some crys ts. of KI in 1400 ml PhMe was added 44.8 g p-FC<sub>6</sub>H<sub>4</sub>CO(CH<sub>2</sub>)<sub>3</sub>Cl. The mixture was refluxed 48 hr worked up and treated with anhydrous HCl to give I (Ar = 4-FC<sub>6</sub>H<sub>4</sub>, n = 3) (Ia).HCl m. 189-90° (iso-PrOH-Et<sub>2</sub>O); Ia maleate m. 132° (MeOH-iso-PrOH). Ia.HCl was also prepared from 7.6 g 3-(3-cyanopropyl)-3-azabicyclo[3.2.2]nonane (hydrochloride m. 260°, from III, Cl(CH<sub>2</sub>)<sub>3</sub>CN, Na<sub>2</sub>CO<sub>3</sub>, and KI in PhMe) in 75 ml Et<sub>2</sub>O and 4-FC<sub>6</sub>H<sub>4</sub>MgBr from 14 g 4-FC<sub>6</sub>H<sub>4</sub>Br and 1.92 g Mg in 40 ml Et<sub>2</sub>O. Reduction of 3 g Ia.HCl by 0.3 g NaBH<sub>4</sub> in 20 ml. 50% MeOH gave II (Ar = 4-FC<sub>6</sub>H<sub>4</sub>, n = 3), m. 70°; HCl salt m. 216-17°. Similarly prepared were the following I (n = 3) (Ar and m.p. HCl salt given). 3-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub>, 210°; 4-MeOC<sub>6</sub>H<sub>4</sub>, 188°; 2-thienyl, 220-2°; 4-PhOC<sub>6</sub>H<sub>4</sub>, 263-5°; 4-ClC<sub>6</sub>H<sub>4</sub>, 242°; 4-tert-BuC<sub>6</sub>H<sub>4</sub>, 244-5°; 3-FC<sub>6</sub>H<sub>4</sub>, - (maleate, m. 139-40°); 3-thienyl, 228°; 4-iso-PrC<sub>6</sub>H<sub>4</sub>, 243°; 4-BrC<sub>6</sub>H<sub>4</sub>, 267-8°; 3,4-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, 247-8°; 2,4-(MeO)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, 182-3°; Ph, 230-2° (MeOH); 4-MeC<sub>6</sub>H<sub>4</sub>, 225-6°; 2,5-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, 203-4°; 4-HOC<sub>6</sub>H<sub>4</sub>, 312-13° (decomposition); and 2,4-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, 203-4°. Also prepared were IV.HCl, m. 158-9° (hemihydrate); I (Ar = p-FC<sub>6</sub>H<sub>4</sub>, n = 4)-HCl, m. 85-6° (dihydrate) [from 3-(4-cyanobutyl)-3-azabicyclo[3.2.2]nonane, hydrochloride, m. 278-9°]; V.HCl, m. 118-20° [from 9-methyl-4-oxo-3,9-diazabicyclo[4.2.1]nonane, m. 88° (petroleum ether), hydrochloride m. 258° (decomposition), through 9-methyl-3,9-diazabicyclo[4.2.1]nonane, dihydrochloride m. 220° (decomposition); and I [Ar = p-FC<sub>6</sub>H<sub>4</sub>, (CH<sub>2</sub>)<sub>n</sub> = CH<sub>2</sub>CHMeCH<sub>2</sub>]. HCl, m. 145-6° [from 3-(3-cyano-2-methyl-1-propyl)-3-azabicyclo[3.2.2]nonane, hydrochloride m. 256° (decomposition). To MeLi (from 0.52 g Li and 10.65 g MeI in 50 ml. Et<sub>2</sub>O) was added 8.7 g Ia in 60 ml C<sub>6</sub>H<sub>6</sub> to give 3-[4-(4-fluorophenyl)-4-hydroxy-4-methyl-1-butyl]-3-azabicyclo[3.2.2]nonane, maleate, m. 123°. I and II have sedative, tranquilizing and antiaggressive properties.

IT 27229-18-1P


RL: SPN (Synthetic preparation); PREP (Preparation)

10/512,559

(preparation of)  
RN 27229-18-1 CAPLUS  
CN Butyrophenone, 4'-fluoro-4-(9-methyl-3,9-diazabicyclo[4.2.1]non-3-yl)-,  
maleate (8CI) (CA INDEX NAME)

CM 1


CRN 47233-13-6  
CMF C18 H25 F N2 O



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



10/512,559

LI ANSWER 17 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1966:103405 CAPLUS

DOCUMENT NUMBER: 64:103405

ORIGINAL REFERENCE NO.: 64:19371c-e

TITLE: Mass spectrometry in structural and stereochemical problems. CI. A study of the fragmentation of some azabicyclo lactams

AUTHOR(S): Duffield, A. M.; Djerassi, Carl; Wise, Lawrence; Paquette, Leo A.

CORPORATE SOURCE: Stanford Univ., Stanford, CA

SOURCE: Journal of Organic Chemistry (1966), 31(5), 1599-1602

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal


LANGUAGE: English

AB cf. CA 64, 5142a, 9559b, 17300c. The mass spectra of 5 azabicyclo lactams (I-V) were measured in order to examine the effect upon the fragmentation pattern of 2 different functional groups in close proximity to each other. From the utilization of deuterated analogs, supplemented by high-resolution mass spectrometry, rationalizations are presented for the principal fragments observed in the spectra of these compds. Increasing the ring size from 8 to 10 membered did not affect greatly the principal fragmentation modes.

IT 1128-77-4, 3,9-Diazabicyclo[4,2,1]nonan-4-one, 3,9-dimethyl-  
7345-18-8, 3,9-Diazabicyclo[4,2,1]nonan-4-one, 3-ethyl-9-methyl-  
(mass spectrum of)


RN 1128-77-4 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonan-4-one, 3,9-dimethyl- (7CI, 8CI) (CA INDEX NAME)



RN 7345-18-8 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonan-4-one, 3-ethyl-9-methyl- (7CI, 8CI) (CA INDEX NAME)



~~1/1~~ ANSWER 18 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1965:82489 CAPLUS

DOCUMENT NUMBER: 62:82489

ORIGINAL REFERENCE NO.: 62:14645a-c

TITLE: Transannular cyclizations in medium-sized unsaturated lactams. Apparent dependence of transannular interaction upon conformational factors

AUTHOR(S): Paquette, Leo A.; Wise, Lawrence D.

CORPORATE SOURCE: Ohio State Univ., Columbus

SOURCE: Journal of the American Chemical Society (1965), 87(7), 1561-6

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 62:82489


AB A series of azabicyclic amides of varying ring size (eight to ten members) are shown to be readily transformed to  $\alpha,\beta$ -unsaturated lactams by the Hofmann elimination procedure. These unsaturated secondary lactams of the azacyclooctane and azacyclononane series undergo transannular cyclization when treated with acids. The related N-methylamides, as well as the azacyclodecane example, merely undergo protonation of the dimethylamino group under identical conditions. These results are discussed in terms of conformational factors.

IT 1128-77-4P, 3,9-Diazabicyclo[4,2,1]nonan-4-one, 3,9-dimethyl-  
1201-54-3P, 3,10-Diazabicyclo[4.3.1]decan-4-one, 3,10-dimethyl-  
1212-71-1P, 3,9-Diazabicyclo[4,2,1]nonan-4-one, 3,9-dimethyl-,  
perchlorate 1603-38-9P, 3-Aza-10-azoniabicyclo[4.3.1]decane,  
3,10,10-trimethyl-4-oxo-, iodide

RL: PREP (Preparation)  
(preparation of)


RN 1128-77-4 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonan-4-one, 3,9-dimethyl- (7CI, 8CI) (CA INDEX NAME)



RN 1201-54-3 CAPLUS

CN 3,10-Diazabicyclo[4.3.1]decan-4-one, 3,10-dimethyl- (7CI, 8CI) (CA INDEX NAME)



RN 1212-71-1 CAPLUS


CN 3,9-Diazabicyclo[4.2.1]nonan-4-one, 3,9-dimethyl-, perchlorate (7CI, 8CI) (CA INDEX NAME)

10/512,559

CM 1

CRN 7601-90-3


CMF Cl H O4



CM 2


CRN 1128-77-4

CMF C9 H16 N2 O



RN 1603-38-9 CAPLUS

CN 3-Aza-10-azoniabicyclo[4.3.1]decane, 3,10,10-trimethyl-4-oxo-, iodide  
(8CI) (CA INDEX NAME)



● I<sup>-</sup>

✓ ANSWER 19 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1964:52805 CAPLUS  
 DOCUMENT NUMBER: 60:52805  
 ORIGINAL REFERENCE NO.: 60:9297g-h,9298a-c  
 TITLE: 3-Acyl-9-methyl-3,9-diazabicyclo[4.2.1]nonanes  
 INVENTOR(S): Wagner, Hans A.  
 PATENT ASSIGNEE(S): G.D. Searle and Co.  
 SOURCE: 3 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3117132		19640107	US 1962-164403	19620104
PRIORITY APPLN. INFO.:			US	19620104

GI For diagram(s), see printed CA Issue.

AB The title compds., possessing antihypertensive, antiinflammatory, and antibacterial properties, and the ability to inhibit the incorporation of mevalonic acid during biosynthesis of cholesterol, are prepared by treating 9-methyl-3,9-diazabicyclo[4.2.1]nonane (I) with acid chlorides. Thus, 42 g. I in 500 ml. Et<sub>2</sub>O is slowly added, with vigorous agitation, to 63 g. Ph<sub>2</sub>CHCOCl in 1 l. Et<sub>2</sub>O, the mixture stirred 1 hr., the solid precipitate collected and dissolved in 500 ml. H<sub>2</sub>O, the aqueous solution adjusted to pH 8 with concentrated

NaOH, the precipitated solid filtered off and taken up in Et<sub>2</sub>O, the filtrate extracted with Et<sub>2</sub>O, the combined Et<sub>2</sub>O solns. dried over CaSO<sub>4</sub> and evaporated, and

the residue recrystd. from hexane to give 9-methyl-3-diphenylacetyl-3,9-diazabicyclo [4.2.1] nonane (II), m. 106°. Similarly prepared are 3-phenylacetyl-, 3-cyclohexylacetyl-, and 3-acetoxy-9-methyl-3,9-diazabicyclo[4.2.1]nonane. I (28 g.) in 100 ml. Et<sub>2</sub>O is treated with 27 g. ClCO<sub>2</sub>-CH<sub>2</sub>CHMe<sub>2</sub> in 250 ml. Et<sub>2</sub>O to give 3-isobutoxycarbonyl-9-methyl-3,9-diazabicyclo[4.2.1]nonane-HCl, m. 208-10° (EtOH-EtOAc). Similarly prepared is 3-(3-cyclopentylpropionyl)-9-methyl-3,9-diazabicyclo[4.2.1]nonane-HCl, m. 233° (EtOH). II (167 g.) and 139 g. p-BrC<sub>6</sub>H<sub>4</sub>COCH<sub>2</sub>Br in 2 l. EtOH is refluxed 5 hrs., allowed to stand overnight, and poured into 30 l. Et<sub>2</sub>O to precipitate

9-(p-bromobenzoylmethyl)-9-methyl-3-diphenylacetyl-3-aza-9-azoniabicyclo[4.2.1]nonane bromide, m. 149° (EtOH-EtOAc). Similarly prepared were the following substituted 3-isobutoxycarbonyl-9-methyl-3-aza-9-azoniabicyclo[4.2.1]nonane bromides (substituent and m.p. given): 9-ethoxycarbonylmethyl, .apprx.125°; 9-(p-bromobenzyl), .apprx.187°; 9-(p-bromobenzoylmethyl), .apprx.192°. Also prepared were 9,9'-p-phenylenedimethylenebis(3-isobutoxycarbonyl-9-methyl-3-aza-9-azoniabicyclo[4.2.1]nonane bromide) monohydrate, m. 172-4°; and 9,9'-o-phenylenedimethylenebis(3-isobutoxycarbonyl-9-methyl-3-aza-9-azoniabicyclo[4.2.1]nonane bromide monohydrate, m. 181-3°. Cf. Michaels and Zaugg, CA 54, 1971ld.

IT 91951-85-8P, 3,9-Diazabicyclo[4.2.1]nonane-3-carboxylic acid, 9-methyl-, methyl ester 93143-82-9P, 3,9-Diazabicyclo[4.2.1]nonane, 3-(cyclohexylacetyl)-9-methyl-96557-59-4P, 3,9-Diazabicyclo[4.2.1]nonane-3-carboxylic acid, 9-methyl-, isobutyl ester, hydrochloride 97646-22-5P, 3,9-Diazabicyclo[4.2.1]nonane, 3-(3-cyclopentylpropionyl)-9-methyl-, hydrochloride 98068-05-4P, 3,9-Diazabicyclo[4.2.1]nonane,


9-methyl-3-(phenylacetyl)- 98271-44-4P, 3,9-Diazabicyclo[4.2.1]nonane, 3-(diphenylacetyl)-9-methyl-100030-08-8P, 9-(p-Bromophenacyl)-3-carboxy-9-methyl-3-aza-9-azoniabicyclo[4.2.1]nonane bromide, isobutyl ester 100211-71-0P, 9-(p-Bromobenzyl)-3-carboxy-9-methyl-3-aza-9-azoniabicyclo[4.2.1]nonane bromide, isobutyl ester 104016-16-2P, 9-(p-Bromophenacyl)-3-(diphenylacetyl)-9-methyl-3-aza-9-azoniabicyclo[4.2.1]nonane bromide

RL: PREP (Preparation)

(preparation of)


RN 91951-85-8 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane-3-carboxylic acid, 9-methyl-, methyl ester (7CI) (CA INDEX NAME)




RN 93143-82-9 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(cyclohexylacetyl)-9-methyl- (7CI) (CA INDEX NAME)



RN 96557-59-4 CAPLUS


CN 3,9-Diazabicyclo[4.2.1]nonane-3-carboxylic acid, 9-methyl-, isobutyl ester, hydrochloride (7CI) (CA INDEX NAME)



● HCl

RN 97646-22-5 CAPLUS


CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(3-cyclopentylpropionyl)-9-methyl-, hydrochloride (7CI) (CA INDEX NAME)



● HCl


RN 98068-05-4 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 9-methyl-3-(phenylacetyl)- (7CI) (CA INDEX NAME)




RN 98271-44-4 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(diphenylacetyl)-9-methyl- (7CI) (CA INDEX NAME)




RN 100030-08-8 CAPLUS


CN 9-(p-Bromophenacyl)-3-carboxy-9-methyl-3-aza-9-azoniabicyclo[4.2.1]nonane bromide, isobutyl ester (7CI) (CA INDEX NAME)

● Br<sup>-</sup>

RN 100211-71-0 CAPLUS

CN 9-(p-Bromobenzyl)-3-carboxy-9-methyl-3-aza-9-azoniabicyclo[4.2.1]nonane  
bromide, isobutyl ester (7CI) (CA INDEX NAME)● Br<sup>-</sup>

RN 104016-16-2 CAPLUS

CN 9-(p-Bromophenacyl)-3-(diphenylacetyl)-9-methyl-3-aza-9-  
azoniabicyclo[4.2.1]nonane bromide (7CI) (CA INDEX NAME)● Br<sup>-</sup>


111 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1962:2410 CAPLUS  
 DOCUMENT NUMBER: 56:2410  
 ORIGINAL REFERENCE NO.: 56:474i,475a-d  
 TITLE: 3,9-Diazabicyclo[4.2.1]nonane derivatives  
 INVENTOR(S): Zaugg, Harold E.  
 PATENT ASSIGNEE(S): Abbott Laboratories  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	US 2999091		19610905	US 1959-848235	19591023
AB	<p>3-Tropanone (11.1 g.) in 100 ml. CHCl<sub>3</sub>, was cooled to -5° and the solution treated dropwise with 25 ml. concentrated H<sub>2</sub>SO<sub>4</sub> below 15°. NaN<sub>3</sub> (10.4 g.) was added in 0.5-g. portions below 35°. After the addns., which required 2 hrs., the mixture was stirred at 50° 2 hrs. The mixture was poured on ice and made alkaline with K<sub>2</sub>CO<sub>3</sub>, then 50 cc. of 60% KOH solution was added. The inorg. salts were removed by filtration and washed with CHCl<sub>3</sub>. The aqueous phase of the filtrate was extracted with CHCl<sub>3</sub> and</p> <p>the combined CHCl<sub>3</sub> solns. were dried with Na<sub>2</sub>SO<sub>4</sub>. After distillation of CHCl<sub>3</sub> there was obtained 90% 9-methyl-3,9-diazabicyclo[4.2.1]nonan-4-one (I); HCl salt m. 258-9° (decomposition). I (11 g.) was reduced by 6.8 g. LiAlH<sub>4</sub> in 600 ml. of Et<sub>2</sub>O at reflux for 46 hrs. to yield 68% 9-methyl-3,9-diazabicyclo[4.2.1]nonane (II), b<sub>38</sub> 111-13° n<sub>24D</sub> 1.4992; di-HCl salt m. 290-1° (decomposition). A solution of 5.9 g. p-chlorobenzhydryl chloride in 20 cc. dry xylene was added to 3.5 g. II and 4.0 g. Et<sub>3</sub>N in 70 cc. of xylene. After refluxing 22 hrs., the mixture was cooled and filtered to remove Et<sub>3</sub>N.HCl. Vacuum evaporation of xylene gave an oil, which treated with oxalic acid in ether gave 0.2 g. oxalate, which furnished 4-(p-chlorobenzhydryl)-9-methyl-4,9-diazabicyclo [4.2.1] nonane (III), m. 91°. 4-Benzhydryl-9-methyl-4,9-diazabicyclo[4.2.1]nonane (IV) was prepared by reaction of II with benzhydryl chloride. II and 9-fluorenyl chloride yielded 4-(9-fluorenyl)9-methyl-4,9-diazabicyclo[4.2.1]nonane. The halophenyl compds., 4-(p,p'-dichlorobenzhydryl)-9-methyl-4,9-diaza [4.2.1]bicyclononane (VI) and 4-(2,4-dichlorobenzhydryl)-9-methyl-4,9-diaza[4.2.1]bicyclononane (VII), are prepared, resp., by treating p,p'-dichlorobenzhydryl chloride and 2,4-dichlorobenzhydryl chloride with II. Compds. such as III-VII have ganglionic-blocking actions and are serotonin antagonists. Hydrogenation at 30 lb. H pressure and 60° with PtO<sub>2</sub> reduced one Ph group of IV to yield 4-(cyclohexylphenylmethyl) - 9 - methyl - 4, 9 - diaza [4.2.1 ] bicyclononane.</p>				
IT	<p>94999-77-6P, 3,9-Diazabicyclo[4.2.1]nonane, 3-(α-cyclohexylbenzyl)-9-methyl- 95005-03-1P, 3,9-Diazabicyclo[4.2.1]nonane, 3-(p-chloro-α-phenylbenzyl)-9-methyl- 95948-57-5P, 3,9-Diazabicyclo[4.2.1]nonane, 3-[bis(p-chlorophenyl)methyl]-9-methyl- 95948-58-6P, 3,9-Diazabicyclo[4.2.1]nonane, 3-(2,4-dichloro-α-phenylbenzyl)-9-methyl- 98131-64-7P, 3,9-Diazabicyclo[4.2.1]nonane, 3-(diphenylmethyl)-9-methyl- 101227-56-9P, 3,9-Diazabicyclo[4.2.1]nonane, 3-(p-chloro-α-phenylbenzyl)-9-methyl-, oxalate          RL: PREP (Preparation)          (preparation of)</p>				
RN	94999-77-6 CAPLUS				

10/512,559


CN 3,9-Diazabicyclo[4.2.1]nonane, 3-( $\alpha$ -cyclohexylbenzyl)-9-methyl-  
(7CI) (CA INDEX NAME)




RN 95005-03-1 CAPLUS  
CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(p-chloro- $\alpha$ -phenylbenzyl)-9-methyl-  
(7CI) (CA INDEX NAME)



RN 95948-57-5 CAPLUS  
CN 3,9-Diazabicyclo[4.2.1]nonane, 3-[bis(p-chlorophenyl)methyl]-9-methyl-  
(7CI) (CA INDEX NAME)




RN 95948-58-6 CAPLUS  
CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(2,4-dichloro- $\alpha$ -phenylbenzyl)-9-methyl-  
(7CI) (CA INDEX NAME)



RN 98131-64-7 CAPLUS

10/512,559

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(diphenylmethyl)-9-methyl- (7CI) (CA INDEX NAME)




RN 101227-56-9 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane, 3-(p-chloro- $\alpha$ -phenylbenzyl)-9-methyl-, oxalate (7CI) (CA INDEX NAME)

CM 1

CRN 95005-03-1


CMF C21 H25 Cl N2



CM 2

CRN 144-62-7

CMF C2 H2 O4



10/512,559

=> => d his

(FILE 'HOME' ENTERED AT 20:38:05 ON 30 JAN 2007)

FILE 'REGISTRY' ENTERED AT 20:38:16 ON 30 JAN 2007

L1	STRUCTURE UPLOADED
L2	QUE L1
L3	4 S L2
L4	STRUCTURE UPLOADED
L5	QUE L4
L6	4 S L5
L7	640 S L2 SSS FUL
L8	141 S L5 SUB=L7 FUL
L9	114 S L8 AND CAPLUS/LC
L10	27 S L8 NOT L9

FILE 'CAPLUS' ENTERED AT 20:41:32 ON 30 JAN 2007


L11	20 S L8
-----	---------

FILE 'REGISTRY' ENTERED AT 20:42:47 ON 30 JAN 2007

=> d 110 25-27

10/512,559

L10 ANSWER 25 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 98146-08-8 REGISTRY  
ED Entered STN: 22 Sep 1985  
CN 3-Carboxy-9-(carboxymethyl)-9-methyl-3-aza-9-azoniabicyclo[4.2.1]nonane  
bromide, 3-isobutyl ethyl ester (7CI) (CA INDEX NAME)  
MF C17 H31 N2 O4 . Br  
SR CAOLD  
LC STN Files: CAOLD  
CRN (740045-29-8)



●  $\text{Br}^-$

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

10/512,559

L10 ANSWER 26 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN

RN 47233-13-6 REGISTRY

ED Entered STN: 16 Nov 1984


CN 1-Butanone, 1-(4-fluorophenyl)-4-(9-methyl-3,9-diazabicyclo[4.2.1]non-3-yl)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 3,9-Diazabicyclo[4.2.1]nonane, 1-butanone deriv.

MF C18 H25 F N2 O


CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/512,559

L10 ANSWER 27 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 3258-76-2 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 3-Aza-9-azoniabicyclo[4.2.1]nonane, 3,9,9-trimethyl-4-oxo-, iodide (8CI)  
(CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 3,9,9-Trimethyl-4-oxo-3-aza-9-azoniabicyclo[4.2.1]nonane iodide (7CI)  
MF C10 H19 N2 O . I  
LC STN Files: CAOLD  
CRN (801144-51-4)



● I<sup>-</sup>

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

10/512,559

=> d 110 20-24

10/512,559

L10 ANSWER 20 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN

RN 740045-29-8 REGISTRY


ED Entered STN: 05 Sep 2004

CN 3-Aza-9-azoniabicyclo[4.2.1]nonane, 9-(2-ethoxy-2-oxoethyl)-9-methyl-3-[(2-methylpropoxy)carbonyl]- (9CI) (CA INDEX NAME)

MF C17 H31 N2 O4


CI COM

SR CA



10/512,559

L10 ANSWER 21 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 731754-04-4 REGISTRY  
ED Entered STN: 23 Aug 2004  
CN 3,9-Diazabicyclo[4.2.1]nonane-3-carboxylic acid, 9-methyl-, 2-methylpropyl  
ester (9CI) (CA INDEX NAME)  
MF C13 H24 N2 O2  
CI COM  
SR CA



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/512,559

L10 ANSWER 22 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN

RN 686257-18-1 REGISTRY


ED Entered STN: 26 May 2004

CN 3-Aza-9-azoniabicyclo[4.2.1]nonane, 9-[(4-bromophenyl)methyl]-9-methyl-3-  
[(2-methylpropoxy)carbonyl]- (9CI) (CA INDEX NAME)

MF C20 H30 Br N2 O2


CI COM

SR CA




10/512,559

L10 ANSWER 23 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 105768-22-7 REGISTRY  
ED Entered STN: 21 Dec 1986  
CN 9,9'-(o-Phenylenedimethylene)bis[3-carboxy-9-methyl-3-aza-9-  
azoniabicyclo[4.2.1]nonane bromide], diisobutyl ester (7CI) (CA INDEX  
NAME)  
MF C34 H56 N4 O4 . 2 Br  
SR CAOLD  
LC STN Files: CAOLD  
CRN (805222-36-0)



● 2 Br<sup>-</sup>




1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


10/512,559

L10 ANSWER 24 OF 27 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 105768-21-6 REGISTRY  
ED Entered STN: 21 Dec 1986  
CN 9,9-(p-Phenylenedimethylene)bis[3-carboxy-9-methyl-3-aza-9-  
azoniabicyclo[4.2.1]nonane bromide], diisobutyl ester (7CI) (CA INDEX  
NAME)  
MF C34 H56 N4 O4 . 2 Br  
SR CAOLD  
LC STN Files: CAOLD  
CRN (804469-03-2)

PAGE 1-A



PAGE 2-A



● 2 Br<sup>-</sup>

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)